Published in Blood Weekly, March 30th, 1998
The Phase III trial is one of the largest sickle cell trials ever conducted with a target of 350 patients in 30 sites throughout the United States. Dr. J. Michael Grindel, CytRx, added, "This study has been powered statistically to confirm what we have already seen in previous tests conducted by ourselves and others. Based on our discussions with the FDA on the endpoints in the study protocol, we believe that if we can show a statistically significant improvement over...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.